• About
  • Advertise
  • Careers
  • Write for us
  • Contact
  • Terms of service
Thursday, May 26, 2022
The Millennial Source
TMS
Home WORLD

68% of severe COVID-19 cases improved with Gilead Sciences’ remdesivir drug

April 11, 2020
in WORLD
Source: Bloomberg

Source: Bloomberg

Share on FacebookShare on TwitterShare on Linkedin



Remdesivir, a drug created by Gilead Sciences (GILD), has been tested on individuals suffering from severe cases of COVID-19. The drug was initially created to treat Ebola patients and was tested in Eastern Congo. 

While it ultimately proved ineffective for treating Ebola, remdesivir was proven to be safe. This fact allowed researchers to expedite human trials when the coronavirus pandemic hit to see if it would be effective on COVID-19.

Now, as acknowledged in a report published in the New England Journal of Medicine, it appears that this experimental drug has shown signs of promise.

The drug was tested on 61 individuals across the United States, Europe and Canada over an 18-day period. Results from eight of these individuals could not be analyzed due to errors in dosing or post-treatment data, but 68% of the remaining 53 patients showed improvements in their conditions. 

Furthermore, of the 30 patients tested who were initially on ventilators, 17 no longer required mechanical ventilation after receiving the drug. Half of the patients tested were discharged and a total of 13% died. The highest mortality rate came among those on a ventilator, a total of 18%.

All of the patients received remdesivir for up to 10 days on a compassionate use basis (which allows for unapproved medicines to be provided to patients who have no other treatment options available.)

If remdesivir is found to be safe and effective in treating COVID-19, the cost per treatment is estimated to be about US$9, the authors of an article in the Journal of Virus Eradication write. In addition, as an intravenous infusion, administration of remdesivir would likely not incur any additional costs beyond those initially estimated.

Remdesivir is now being studied in five large clinical trials, two of which could deliver results this month. 

With 1.5 million individual dosages, enough for over 140,000 patients, individuals infected with COVID-19 can access the drug on a compassionate use basis at no charge. 

The maker of the drug has ramped up production of remdesivir, setting the “ambitious goal” of producing more than half a million treatment courses by October and one million by the end of 2020.

[article_ad]

Have a tip or story? Get in touch with our reporters here! 

Sign up for daily news briefs from The Millennial Source here!

Related

Tags: Short read
Share7TweetShare

Latest Posts

Trump warns Iran of “1,000 times greater” response to any assassination plot or attack on US

Trump warns Iran of “1,000 times greater” response to any assassination plot or attack on US

September 17, 2020
world reacts to uae and israel normalising diplomatic ties

World reacts to UAE and Israel move to normalize diplomatic ties

August 14, 2020
Justice Department accuses Yale University of racial discrimination in undergraduate admissions process

US Department of Justice accuses Yale University of racial discrimination in admissions process

August 14, 2020

Resurgence of COVID-19 potentially theatens New Zealand election date

August 13, 2020

Biden and Harris pledge to lead America out of crisis in first public event since VP announcement

August 13, 2020

Jimmy Lai released on bail as Next Digital stock price soars

August 12, 2020

History made as Joe Biden picks Kamala Harris for his vice-presidential 2020 election running mate

August 12, 2020

Russian vaccine becomes the first coronavirus vaccine to be approved, but concerns linger over rushed testing process

August 11, 2020

Seattle police chief retires after city council votes to cut US$3.5 million from the police budget

August 11, 2020

SUBSCRIBE TO THE TMS NEWSLETTER

By providing your email, you agree to our Privacy Policy

The Millennial Source Ltd. 2021

No Result
View All Result
  • Your daily briefing
  • About us
  • Explore
    • Startups
    • Climate change
    • Tech giants
    • Crypto
    • The future of work
    • Banking giants
    • Economy
  • Lifestyle
  • TMS archives
  • Write for us
  • Contact
  • Privacy Policy & Terms

© 2022 The Millennial Source Ltd.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

string(24) "jsonld single post debug"
The Millennial Source
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.